A retrospective study comparing EUS-BD and ERCP-BD after duodenal stent placement in patients with malignant biliary and duodenal obstruction.

IF 2 4区医学 Q2 SURGERY

Minimally Invasive Therapy & Allied Technologies Pub Date : 2025-10-01 Epub Date: 2025-07-25 DOI:10.1080/13645706.2025.2537407

Mitsuru Sugimoto, Tadayuki Takagi, Rei Suzuki, Hiroyuki Asama, Hiroshi Shimizu, Kentaro Sato, Rei Ohira, Jun Nakamura, Mika Takasumi, Tsunetaka Kato, Takumi Yanagita, Mitsuru Otsuka, Takuto Hikichi, Hiromasa Ohira

{"title":"A retrospective study comparing EUS-BD and ERCP-BD after duodenal stent placement in patients with malignant biliary and duodenal obstruction.","authors":"Mitsuru Sugimoto, Tadayuki Takagi, Rei Suzuki, Hiroyuki Asama, Hiroshi Shimizu, Kentaro Sato, Rei Ohira, Jun Nakamura, Mika Takasumi, Tsunetaka Kato, Takumi Yanagita, Mitsuru Otsuka, Takuto Hikichi, Hiromasa Ohira","doi":"10.1080/13645706.2025.2537407","DOIUrl":null,"url":null,"abstract":"Background: In patients with malignant biliary and duodenal obstruction (MBDO), biliary and duodenal double stenting is necessary. However, whether the time to recurrent biliary obstruction (TRBO) can be extended with ERCP-guided biliary drainage (ERCP-BD) or EUS-guided BD (EUS-BD) has not been sufficiently elucidated. Therefore, the aim of this study was to determine whether ERCP-BD or EUS-BD was more useful for increasing the TRBO with duodenal stenting.Methods: We compared the TRBO with duodenal stenting and other clinical outcomes between ERCP-BD and EUS-BD in MBDO patients. We matched the patient characteristics of the two groups using propensity scores.Results: Technical success was greater in the EUS-BD group (n = 17/17, 100%) than in the ERCP-BD group (n = 32/52, 61.5%) (p < 0.01). After propensity score matching, 17 matched pairs were included for further analysis. There was no significant difference in the TRBO following duodenal stenting between the ERCP-BD group (median of 62 days) and the EUS-BD group (median of 68 days) (p = 0.94).Conclusion: The TRBO following duodenal stenting was comparable between ERCP-BD and EUS-BD. The technical success of EUS-BD was superior to that of ERCP-BD; therefore, EUS-BD might be the optimal choice for endoscopic BD in MBDO patients.","PeriodicalId":18537,"journal":{"name":"Minimally Invasive Therapy & Allied Technologies","volume":" ","pages":"424-432"},"PeriodicalIF":2.0000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minimally Invasive Therapy & Allied Technologies","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13645706.2025.2537407","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In patients with malignant biliary and duodenal obstruction (MBDO), biliary and duodenal double stenting is necessary. However, whether the time to recurrent biliary obstruction (TRBO) can be extended with ERCP-guided biliary drainage (ERCP-BD) or EUS-guided BD (EUS-BD) has not been sufficiently elucidated. Therefore, the aim of this study was to determine whether ERCP-BD or EUS-BD was more useful for increasing the TRBO with duodenal stenting.

Methods: We compared the TRBO with duodenal stenting and other clinical outcomes between ERCP-BD and EUS-BD in MBDO patients. We matched the patient characteristics of the two groups using propensity scores.

Results: Technical success was greater in the EUS-BD group (n = 17/17, 100%) than in the ERCP-BD group (n = 32/52, 61.5%) (p < 0.01). After propensity score matching, 17 matched pairs were included for further analysis. There was no significant difference in the TRBO following duodenal stenting between the ERCP-BD group (median of 62 days) and the EUS-BD group (median of 68 days) (p = 0.94).

Conclusion: The TRBO following duodenal stenting was comparable between ERCP-BD and EUS-BD. The technical success of EUS-BD was superior to that of ERCP-BD; therefore, EUS-BD might be the optimal choice for endoscopic BD in MBDO patients.

查看原文本刊更多论文

一项回顾性研究比较EUS-BD和ERCP-BD在恶性胆道和十二指肠梗阻患者植入十二指肠支架后的疗效。

背景：在恶性胆道和十二指肠梗阻（MBDO）患者中，胆道和十二指肠双支架植入术是必要的。然而，ercp引导的胆道引流（ERCP-BD）或eus引导的BD （EUS-BD）是否可以延长复发性胆道梗阻（TRBO）的时间还没有得到充分的阐明。因此，本研究的目的是确定ERCP-BD或EUS-BD是否更有助于增加十二指肠支架植入术的TRBO。方法：比较TRBO与十二指肠支架植入术以及ERCP-BD与EUS-BD治疗MBDO患者的其他临床结果。我们使用倾向评分来匹配两组患者的特征。结果：EUS-BD组技术成功率（n = 17/17, 100%）高于ERCP-BD组（n = 32/52, 61.5%）（p = 0.94）。结论：ERCP-BD和EUS-BD十二指肠支架植入术后的TRBO具有可比性。EUS-BD的技术成功率优于ERCP-BD；因此，EUS-BD可能是MBDO患者内镜下BD的最佳选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Minimally Invasive Therapy & Allied Technologies 医学-外科

CiteScore

3.80

自引率

5.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Minimally Invasive Therapy and Allied Technologies (MITAT) is an international forum for endoscopic surgeons, interventional radiologists and industrial instrument manufacturers. It is the official journal of the Society for Medical Innovation and Technology (SMIT) whose membership includes representatives from a broad spectrum of medical specialities, instrument manufacturing and research. The journal brings the latest developments and innovations in minimally invasive therapy to its readers. What makes Minimally Invasive Therapy and Allied Technologies unique is that we publish one or two special issues each year, which are devoted to a specific theme. Key topics covered by the journal include: interventional radiology, endoscopic surgery, imaging technology, manipulators and robotics for surgery and education and training for MIS.